Customer Center
Login | Register

Yearly Archives: 2014

If You Think Ebola Was Bad…

December 17th, 2014 / Luminex Corporation

Despite the fact that only a handful of people have been infected with Ebola in the United States, widespread public anxiety and media coverage have quickly escalated the virus to the forefront of public health fears. While these concerns are justified, another imminent threat with little to no public awareness is rapidly spreading – antibiotic resistance.

December 2014: Recent Papers Using Luminex xMAP Technology

December 17th, 2014 / Luminex Corporation

As 2014 comes to a close, we have one last highlight of the numerous publications from our customers. We’ve selected seven new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you. Our bibliography helps you stay current with the success that your scientific peers are having while using

Continue reading »

Flu Vaccine Mismatch

December 12th, 2014 / Luminex Corporation

This year’s flu vaccine may not adequately protect recipients from the currently circulating strains of influenza. While we remain in the early stages of the 2014-2015 flu season, over 90 percent of the 1,200 samples submitted to The Centers for Disease Control and Prevention (CDC) have been the H3N2 subtype of influenza A, half of which are genetically drifted strains against which this season’s flu vaccine offers poor protection.

Premiere of Testimonial Series

December 5th, 2014 / Luminex Corporation

We are pleased to announce the premiere of its first video testimonial in a series titled In Their Own Words. The video features Nikki Fette, Clinical Laboratory Scientist at Parkview Medical Center, located in Pueblo, Colorado.

Designing Your Nucleic Acid Based Assay is Easy!

December 2nd, 2014 / Cassie Bannister

You do not have to struggle to teach yourself how to design your first Luminex-based nucleic acid assay. We have the classes to help you master the art of assay design. Get ready for the year ahead by joining us for fun and informative classes now! Here is a taste of the content from the

Continue reading »

Don’t Fear Protein Assay Development—Luminex is here!

November 26th, 2014 / Eva Oleksy

Are you hiding in the shadows of your laboratory in fear and frustration….wondering how and when you will be saved from the ever-common dilemma of… dun, dun, dun…protein assay development block?!? Never fear… the Luminex Training team can come to the rescue! When you are pondering the question – ‘how do I begin to develop

Continue reading »

November 2014: Recent Papers Using Luminex xMAP Technology

November 24th, 2014 / Luminex Corporation

Another month has passed and it’s time to share the highlights of the numerous publications from our customers. We’ve selected six new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you. Our bibliography helps you stay current with the success that your scientific peers are having while using

Continue reading »

The Trouble with Antibiotics

November 24th, 2014 / Luminex Corporation

A recent investigation by PBS’ Frontline has shed additional light on the growing threat of antibiotic resistance. A segment titled “The Trouble with Antibiotics” delves into mounting evidence of the global spread of multi-drug resistant bacteria, highlighting the case of Troy Stulen, a 20-year-old who was killed by an antibiotic-resistant bacterial infection following a successful bone marrow transplant at the National Institutes of Health in Bethesda, Maryland.

Why Toxins?

November 20th, 2014 / Cassie Bannister

The xMAP® Biothreat Toxin Panel (BTP) was designed to fill a capability gap that exists for a variety of U.S. government and some private sector customers. Although there are some very good high performance single-plex assays as well as lower performance simple-to-use lateral flow assays, there has been a general lack of commercially available high performance multiplex assays for protein-based and small molecule toxins. Therefore, the BTP was designed to fill this need for a high-performance (high sensitivity) multiplex screening assay.

Increased Readmission Rates for Survivors of Septic Shock

November 18th, 2014 / Nanosphere, A Luminex Company

While advances in the understanding of sepsis have led to improved management and outcomes for patients with septic shock, a recent study published in Critical Care Medicine by researchers at the University of Pennsylvania describe a troubling increase in 30-day hospital readmission rates for survivors of septic shock.